CN Patent

CN112251436A — 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸

Assigned to Biomarin Technologies BV · Expires 2021-01-22 · 5y expired

What this patent protects

本发明涉及治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的RNA调节性寡核苷酸。具体地，本发明提供改善的寡核苷酸和其用于治疗、缓解、预防和/或延迟DMD或BMD的应用。

USPTO Abstract

本发明涉及治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的RNA调节性寡核苷酸。具体地，本发明提供改善的寡核苷酸和其用于治疗、缓解、预防和/或延迟DMD或BMD的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN112251436A
Jurisdiction
CN
Classification
—
Expires
2021-01-22
Drug substance claim
No
Drug product claim
No
Assignee
Biomarin Technologies BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.